We are the combination of four hospitals: the General Hospital, the Children’s Hospital, the Women’s Hospital and the Traumatology, Rehabilitation and Burns Hospital. We are part of the Vall d’Hebron Barcelona Hospital Campus: a world-leading health park where healthcare plays a crucial role.
Patients are the centre and the core of our system. We are professionals committed to quality care and our organizational structure breaks down the traditional boundaries between departments and professional groups, with an exclusive model of knowledge areas.
Would you like to know what your stay at Vall d'Hebron will be like? Here you will find all the information.
The commitment of Vall d'Hebron University Hospital to innovation allows us to be at the forefront of medicine, providing first class care adapted to the changing needs of each patient.
Vaccine
This clinical trial is part of the European project RBDCOV, led by HIPRA in which Vall d'Hebron participates, whose recruitment is still open.
Vall d'Hebron and four other hospitals in Spain are conducting a clinical trial to study the safety, immunogenicity and efficacy of a booster dose of the COVID-19 adjuvanted recombinant protein vaccine (BIMERVAX®) from the biotech company HIPRA in healthy adolescents. So far, 150 participants have already been included in the study, and preliminary data show optimistic results for the vaccination of this group.
Based on the data obtained so far, it has already been confirmed that this vaccine has proven to be safe, low reactogenic and able to reactivate the immune response against COVID-19, also with respect to currently circulating variants.
“With these initial results we see that it is a suitable vaccine for the pediatric population. It is important to continue research in order to have more robust data that will allow us to have a recombinant vaccine as a booster also in the pediatric population. To this end, it is important to recruit the 300 volunteers needed to complete this study and initiate it in children under 12 years of age”, assures Dr. Pere Soler Palacín, principal investigator of the project, head of the Infectious Pathology and Immunodeficiency Unit of Paediatrics at Vall d'Hebron University Hospital and of the Infection and Immunity in Paediatric Patients group at Vall d’Hebron Research Institute (VHIR).
The study will include a total of 300 adolescents aged between 12 and 18 years, who have already received two doses of Pfizer's Comirnaty at least six months ago, whether they have passed the COVID-19 or not. In this trial, in addition to Vall d'Hebron, Hospital Josep Trueta (Girona), Hospital Universitario de la Paz (Madrid) and the hospitals HM Montepríncipe and Puerta del Sur (Madrid) are participating.
The search for volunteers is still open
Parents or tutors of minors interested in participating in this study can still do so to collaborate in the research of this vaccine, which has been completely developed and manufactured by the biotechnology company HIPRA in our country. To do so, they should contact the team responsible for the work by e-mail or telephone:
The RBDCOV project
This clinical trial is part of the "RBD Dimer recombinant protein vaccine against SARSCoV2" (RBDCOV) project, within the Horizon Europe program. The objective is to test the efficacy, tolerability and safety of HIPRA's recombinant COVID-19 vaccine in children (including adolescents) and immunocompromised individuals.
RBDCOV is one of the international projects committed to test the vaccine against COVID-19 and allows the creation of links with other European initiatives to reinforce existing research infrastructures.
Paediatric Infectious Diseases and Immunodeficiencies Unit, Children's Hospital and Woman's Hospital
The acceptance of these terms implies that you give your consent to the processing of your personal data for the provision of the services you request through this portal and, if applicable, to carry out the necessary procedures with the administrations or public entities involved in the processing. You may exercise the mentioned rights by writing to web@vallhebron.cat, clearly indicating in the subject line “Exercise of LOPD rights”. Responsible entity: Vall d’Hebron University Hospital (Catalan Institute of Health). Purpose: Subscription to the Vall d’Hebron Barcelona Hospital Campus newsletter, where you will receive news, activities, and relevant information. Legal basis: Consent of the data subject. Data sharing: If applicable, with VHIR. No other data transfers are foreseen. No international transfer of personal data is foreseen. Rights: Access, rectification, deletion, and data portability, as well as restriction and objection to its processing. The user may revoke their consent at any time. Source: The data subject. Additional information: Additional information can be found at https://hospital.vallhebron.com/es/politica-de-proteccion-de-datos.